Tyrosinase

Tyrosinase: A Comprehensive Encyclopedic Reference

1. Identity: Nomenclature, Chemical Classification, and Natural Sources

1.1 Nomenclature and Classification

The tyrosinase enzyme (EC 1.14.18.1) is an oxidoreductase within the general enzyme classification and is involved in the oxidation and reduction process in the epidermis. It is also known by several synonyms reflecting its diverse activities: also known as monophenol oxidase, monophenol monooxygenase, N-acetyl-6-hydroxytryptophan oxidase, phenolase, tyrosine-dopa oxidase, and cresolase. Tyrosinase (TYR) is a type-3 copper enzyme that catalyzes the key steps of melanogenesis, namely the two-step oxidation of monophenols to catechols and their subsequent conversion into ortho-quinones.

1.2 Natural Sources and Distribution

Tyrosinase is a copper-containing enzyme present in plant and animal tissues that catalyzes the production of melanin and other pigments from tyrosine by oxidation. This enzyme is present in bacteria, fungi, plants and animals, and plays multiple roles in pigmentation, wound healing, radiation protection, primary immune responses, and the undesirable browning of fruits and vegetables.

The best-characterized tyrosinases are derived from Streptomyces glaucescens and the fungi Neurospora crassa and Agaricus bisporus. The enzyme extracted from the champignon mushroom Agaricus bisporus is highly homologous with the mammalian ones, and this renders it well suited as a model for studies on melanogenesis. In fact, almost all studies on tyrosinase inhibition conducted so far have used mushroom tyrosinase because the enzyme is commercially available. In mammals, it is found inside melanosomes, which are synthesized in the skin melanocytes.

The physiological role of tyrosinases is related to melanin biosynthesis and has been extracted from different sources such as fungi, fruits, and mammalian melanoma tumors. In plants, the physiological substrates are a variety of phenolics and tyrosinase oxidizes them in the browning pathway observed when tissues are injured.

1.3 Structural Features and Active Site

The three-dimensional structure and functional aspects of tyrosinases from various sources highlight their di-metal ion coordination crucial for catalytic activity. The H subunit contains a binuclear copper-binding site in the deoxy-state, in which three histidine residues coordinate each copper ion. The full fungal tyrosinase complex from Agaricus bisporus has been structurally characterized: the complex comprises two H subunits of approximately 392 residues and two L subunits of approximately 150 residues. These PPO enzymes are dicopper-containing enzymes, which contain two copper atoms at their active site, each bound with three histidine residues.

The structure and catalytic mechanism of mammalian tyrosinases have been extensively studied but are not completely understood because of the lack of information on the tertiary structure. The availability of crystallographic data of one plant catechol oxidase and one bacterial tyrosinase has improved the model of the three-dimensional structure of the active site of the enzyme. Furthermore, sequence comparison of tyrosinase and the TYRPs reveals that the three orthologue proteins share many key structural features, because of their common origin from an ancestral gene, although the specific residues responsible for their different catalytic capabilities have not been identified yet.

1.4 Common Forms and Preparations

Tyrosinase is a multifunctional, glycosylated, and copper-containing oxidase, which catalyzes the first two steps in mammalian melanogenesis and is responsible for enzymatic browning reactions in damaged fruits during post-harvest handling and processing. In research and industrial contexts, it is routinely purified from mushroom (Agaricus bisporus) and made commercially available as a lyophilized powder for laboratory and industrial use. The conversion of phenols to o-diphenols by tyrosinase is a potentially attractive catalytic ability, and thus tyrosinase has attracted a lot of attention with respect to its biotechnological application, as the catechol products are useful as drugs or drug synthons, for example, L-DOPA.

2. Traditional and Historical Use

2.1 Plant-Derived Traditions of Tyrosinase Modulation

Tyrosinase itself is not a traditional herbal supplement in the sense of a botanical extract taken orally. However, the enzyme occupies a central position in the long history of human engagement with natural pigmentation and skin-tone preparations. Many traditional medicinal plant preparations whose primary effects were later understood to result from tyrosinase inhibition have roots in East and Southeast Asian, South Asian, and Mediterranean traditions.

Anthraquinones from different plant sources have been widely used since ancient times due to their laxative and cathartic properties, and several of these compounds were subsequently found to possess anti-tyrosinase activity. Mulberry (Morus alba), whose root bark and fruit have been used in traditional Chinese medicine for centuries in preparations targeting skin brightness and complexion, has been identified as containing highly active tyrosinase inhibitors: previous studies have identified strong tyrosinase inhibitory activity in plants of the family Moraceae, especially Morus alba and Ficus auriculata. The active compounds with tyrosinase inhibitory activity include flavones (30%), flavanones (14%), and 2-arylbenzofurans (10%), and their inhibitory effect was comparable to that of kojic acid.

In the food technology sphere, the browning of cut fruits and vegetables — a process mediated by tyrosinase — has been managed empirically for centuries through the use of ascorbic acid-rich citrus juices and acidifying agents, a practice predating the scientific identification of the enzyme. Unfavorable enzymatic browning of plant-derived foods by tyrosinase causes a decrease in nutritional quality and economic loss of food products, a problem that has driven both traditional food preservation practices and modern research.

Tyrosinase plays an important role in the developmental and defensive functions of insects, as it is involved in wound healing, parasite encapsulation, and sclerotization, features that were observed and exploited in traditional contexts involving insect-derived products in several Asian cultures.

2.2 Tyrosinase in the History of Biochemical Discovery

In 1950, Fitzpatrick et al. demonstrated the presence of tyrosinase in melanocytes of peripheral tissues, which fueled the understanding of the role of this enzyme in the biosynthesis of melanin in melanocytes, with DOPAquinone as an intermediate. It was first characterized in mammals for its role in the development of melanomas and for implication in pigmentation troubles such as albinism and vitiligo. Kojic acid was used for decades in the cosmetic industry as an antimelanogenic agent, representing one of the earliest systematic industrial applications of tyrosinase-related chemistry.

3. Key Constituents, Active Compounds, and Mechanisms of Action

3.1 Enzymatic Activity: Dual Oxidase Function

Tyrosinase catalyzes hydroxylation of monophenols (cresolase activity) and oxidation of diphenols (catecholase activity) in the presence of molecular oxygen. Tyrosinase is mainly involved in two distinct reactions of melanin synthesis: first, the hydroxylation of tyrosine to 3,4-dihydroxyphenylalanine (DOPA), and second, the conversion of DOPA to the corresponding dopaquinone. Dopaquinone undergoes several reactions to eventually form melanin.

Although melanin biosynthesis is complex and involves several steps, a single enzyme known as tyrosinase is key to regulating this process. The melanogenesis pathway is initiated by oxidation of the starting material L-tyrosine (or L-DOPA) to dopaquinone by tyrosinase; the resulting quinone then serves as a substrate for subsequent steps that eventually lead to production of melanin.

3.2 Copper Coordination and the Catalytic Mechanism

The H subunit contains a binuclear copper-binding site in the deoxy-state, in which three histidine residues coordinate each copper ion. The side chains of these histidines have their orientation fixed by hydrogen bonds or, in the case of His85, by a thioether bridge with the side chain of Cys83. The biochemical pathway catalyzed by tyrosinase involves specifically the oxidation of L-tyrosine to L-dopaquinone, a precursor in melanin synthesis.

3.3 Tyrosinase-Related Proteins (TYRPs)

The tyrosinase-related protein (Tyrp1) and dopachrome tautomerase (Dtc), which encode for proteins implicated in melanin synthesis, are the common regulatory elements of exon/intron structure. The development of the three types of vertebrate pigment cells, although different, thus converge at a certain point to allow the expression of members of the tyrosinase family in order to produce melanin pigments.

3.4 Regulation of Tyrosinase Activity

One regulatory pathway involves activation of POMC, with the production of POMC peptides including MSH and ACTH, which increase intracellular cAMP levels, which activates the MITF, and helps to stimulate tyrosinase (TYR) expression and activity. The proliferation of epidermal surface cells and melanocytes is stimulated by cellular signaling receptors, factors, or mediators including endothelin-1, α-melanocyte-stimulating hormone, nitric oxide, histamine, paired box 3, microphthalmia-associated transcription factor, pyrimidine dimer, ceramide, stem cell factors, melanocortin-1 receptor, and cAMP.

3.5 Melanin Types Produced

The process of melanogenesis is related to melanin formation, a heteropolymer of indolic nature that provides the different tonalities in the skin and helps in protection from ultraviolet radiation. Melanin is a phenolic biopolymer and is distributed widely in animal skin and hair to protect the skin against UV radiation from the sun and reactive oxygen species. In fungi, melanins are involved in defence mechanisms against stress factors such as UV or gamma radiation, free radicals, dehydration, and extreme temperatures. The stability of fungal spores also benefits from the protective role of melanin.

4. Scientific Evidence by Area of Use

4.1 Skin Hyperpigmentation Disorders

Tyrosinase is known to be a key enzyme in melanin biosynthesis, involved in determining the color of mammalian skin and hair. Various dermatological disorders, such as melasma, age spots, and sites of actinic damage, arise from the accumulation of an excessive level of epidermal pigmentation. Tyrosinase is the rate-limiting enzyme of melanin production and, accordingly, is the most prominent target to inhibit hyperpigmentation.

Evidence on Inhibitor Efficacy in Humans: Numerous tyrosinase inhibitors have been identified, but most of those lack clinical efficacy because they were identified using mushroom tyrosinase as the target. Using recombinant human tyrosinase to screen a library of 50,000 compounds and comparing active screening hits with well-known whitening ingredients, it was found that hydroquinone and its derivative arbutin only weakly inhibited human tyrosinase with a half-maximal inhibitory concentration (IC50) in the millimolar range, while kojic acid showed a weak efficacy (IC50 > 400 μM).

The most potent inhibitors of human tyrosinase identified in this screen were resorcinyl-thiazole derivatives, especially the newly identified thiamidol (isobutylamido thiazolyl resorcinol), which had an IC50 of 1.1 μM.

Thiamidol Clinical Evidence: Recently, isobutylamido-thiazolyl-resorcinol (Thiamidol) was described as a very potent inhibitor of human tyrosinase. In a controlled clinical study, suction blister-induced post-inflammatory hyperpigmentation (PIH) was treated with a formulation containing Thiamidol or a vehicle for 3 months, and the changes in hyperpigmentation were monitored by spectroscopic measurements. The effect of skin care formulations containing Thiamidol on acne-related PIH was also investigated in two studies: a vehicle-controlled, double-blinded, randomized clinical study and a clinical observational study, both with a duration of 3 months, including clinical photography, clinical grading, and melanin index measurements.

KT-939 Clinical Evidence (2025): A 28-day, single-center clinical study in healthy women with sensitive skin assessed the effects of 0.2% KT-939 lotion on pigmentation and tolerability. KT-939 strongly inhibited human tyrosinase (IC50 = 0.07 μM), demonstrating approximately 4-fold greater potency than Thiamidol. In melanocytes, KT-939 reduced melanin production (IC50 = 0.36 μM) with reversible effects upon withdrawal. Clinically, 28 days of KT-939 lotion use improved skin spot lightening, tone uniformity, and overall brightness, with good tolerability in sensitive skin. This represents very preliminary (single-center, open) human evidence for this novel class.

Deoxyarbutin: Deoxyarbutin showed significant improvements in solar lentigines and overall skin brightness in human clinical trials without cytotoxicity. Evidence for deoxyarbutin is more robust than for many other natural tyrosinase-targeting agents, though it remains limited in the number and size of trials.

Evidence strength summary: The overall evidence for topically applied tyrosinase inhibitors in human hyperpigmentation is moderate. Randomized controlled trials exist for a handful of compounds (thiamidol, kojic acid, certain arbutin derivatives), but most natural-source inhibitors have only in vitro or animal data. A key limitation acknowledged in the literature is that most identified inhibitors lack clinical efficacy because they were identified using mushroom tyrosinase as the target, meaning in vitro activity against fungal enzyme often does not translate to human effect.

4.2 Oculocutaneous Albinism (OCA) and Genetic Pigmentation Disorders

Oculocutaneous albinism (OCA) is a heterogeneous group of autosomal recessive disorders resulting from mutations of the tyrosinase (TYR) gene and presents with either complete or partial absence of pigment in the skin, hair, and eyes due to a defect in an enzyme involved in the production of melanin.

OCA1 results from mutations of the tyrosinase gene and presents with the life-long absence of melanin pigment after birth (OCA1A) or with the development of minimal-to-moderate amounts of cutaneous and ocular pigment (OCA1B). Oculocutaneous albinism type 1 (OCA1) is caused by pathogenic variants in the TYR (tyrosinase) gene which encodes the critical and rate-limiting enzyme in melanin synthesis. It is the most common OCA subtype found in Caucasians, accounting for approximately 50% of cases worldwide.

OCA's symptoms include poor visual acuity, nystagmus, iris transillumination, strabismus, photophobia, foveal hypoplasia, and misrouting of the optic nerve fibers at the chiasm. Frameshift mutations can lead to the loss of the entire copper-binding tyrosinase domain and the only transmembrane melanosome-bound tyrosinase helix. Similarly, premature stop codons result in the loss of approximately two-thirds of the copper-binding tyrosinase domain and the transmembrane helix, signifying a substantial disturbance in the normal function of tyrosinase.

Evidence strength: Genetic linkage between TYR gene mutations and OCA1 is established at the clinical-molecular level, with strong evidence from sequencing studies across multiple patient populations. This is diagnostic rather than therapeutic; there are currently no approved pharmacological agents that directly restore mutant tyrosinase function in OCA1.

4.3 Tyrosinase as a Melanoma Biomarker and Immunotherapy Target

Tyrosinase (EC 1.14.18.1), the key enzyme in melanin synthesis, has been shown to be one of the targets for cytotoxic T-cell recognition in melanoma patients. The tyrosinase gene was found to be active in all tested melanoma samples and in most melanoma cell lines. Among normal cells, only melanocytes appear to express the gene. The tyrosinase antigen presented by HLA-A2 may therefore constitute a useful target for specific immunotherapy of melanoma.

In one clinical trial, 5 clinical responses occurred in 16 metastatic melanoma patients treated with tyrosinase 370D and gp100 210M peptides restricted to HLA class I A*0201. The peptides were modified to increase immunogenicity by altering one amino acid from the wild type and were pulsed into dendritic cells derived by incubation of peripheral blood mononuclear cells with IL-4 and GM-CSF. Among five patients having a CTL response to gp100 or tyrosinase, four were clinically stable or had tumor regression.

Using four-color ImmunoSpot assays with peptide pools covering the sequence of tyrosinase (Tyr), melanoma-associated antigen A3 (MAGE-A3), Melan-A/MART-1, gp100, and NY-ESO-1, the melanoma antigen-specific CD8+ cell repertoire was characterized in PBMC of 40 healthy human donors. Tyr triggered interferon gamma (IFN-γ)-secreting CD8+ T cells in 25% of healthy donors within 24 hours of antigen stimulation ex vivo.

Possible adverse effects of antityrosinase immunization, such as the destruction of normal melanocytes and its consequences, will have to be examined before clinical pilot studies can be undertaken.

Evidence strength: Preclinical and early-phase clinical evidence supports tyrosinase as a melanoma-associated antigen of immunological relevance. Large randomized trials specifically testing tyrosinase-targeted vaccines have not been completed, and the field has largely been superseded by checkpoint inhibitor immunotherapy. This area represents moderate-quality early clinical evidence.

4.4 Neurodegeneration: Parkinson's Disease and Neuromelanin

The dark pigment neuromelanin (NM) is abundant in cell bodies of dopamine (DA) neurons in the substantia nigra (SN) and norepinephrine (NE) neurons in the locus coeruleus (LC) in the human brain. During the progression of Parkinson's disease (PD), together with the degeneration of the respective catecholamine (CA) neurons, the NM levels in the SN and LC markedly decrease.

The biosynthesis pathway of NM in the human brain has been controversial because the presence of tyrosinase in catecholamine neurons in the SN and LC has been elusive. The synthesis of human NM is regarded to be similar to that of melanin in melanocytes: melanin synthesis in skin is via DOPAquinone (DQ) by tyrosinase, whereas NM synthesis in DA neurons is via DAquinone (DAQ) by tyrosine hydroxylase (TH) and aromatic L-amino acid decarboxylase (AADC).

In Parkinson's disease (PD) there is a selective degeneration of neuromelanin-containing neurons, especially substantia nigra dopaminergic neurons. In humans, neuromelanin accumulates with age, the latter being the main risk factor for PD. Key animal research has demonstrated that overexpression of human tyrosinase in rat substantia nigra results in age-dependent production of human-like neuromelanin within nigral dopaminergic neurons, up to levels reached in elderly humans. In these animals, intracellular neuromelanin accumulation above a specific threshold is associated with an age-dependent PD phenotype, including hypokinesia, Lewy body-like formation, and nigrostriatal neurodegeneration.

Oxidized metabolites of dopamine known as dopamine quinone derivatives are thought to play a pivotal role in the degeneration of nigrostriatal dopaminergic neurons in Parkinson's disease. Although such quinone derivatives are usually produced via the autoxidation of catecholamines, tyrosinase, which is a key enzyme in melanin biosynthesis via the production of DOPA and subsequent molecules, can potentially accelerate the induction of catecholamine quinone derivatives by its oxidase activity.

Evidence strength: The relationship between tyrosinase, neuromelanin, and Parkinson's disease is a highly active area of basic research. The causal mechanisms remain incompletely established, and evidence is largely derived from animal models and post-mortem human brain studies. No clinical trials directly targeting tyrosinase for Parkinson's disease treatment have been reported in the peer-reviewed literature.

4.5 Food Browning and Agricultural Applications

Tyrosinase catalyzes the oxidation of phenolic compounds to the corresponding quinones, which is responsible for enzymatic browning in vegetables and fruits. Unfavorable enzymatic browning of plant-derived foods by tyrosinase causes a decrease in nutritional quality and economic loss of food products. The appearance of brown pigments in fruits and vegetables due to tyrosinase activity is a leading cause of postharvest losses.

This application domain is technically established, though it is an industrial/food science concern rather than a human health supplement indication. Inhibitors such as ascorbic acid, citric acid, and various plant extracts are used commercially; evidence at this level is well-documented in applied food science literature.

4.6 Wound Healing, Immune Function, and Other Roles

Tyrosinases are associated with wound healing and with the immune response in plants. In the past decade, many natural and synthetic tyrosinase inhibitors have been evaluated, with many reported to also possess intrinsic antibacterial activity. Further, the enzyme product melanin has been shown to compromise the activity of traditional antibiotics.

Evidence strength: Evidence for the direct role of tyrosinase (or tyrosinase-derived products such as melanin) in human wound healing and immune modulation is largely preclinical — derived from in vitro and invertebrate model studies. No human clinical trials directly testing tyrosinase preparations for wound healing have been identified in the peer-reviewed literature.

5. Body Systems and Health Areas

• Integumentary system (skin, hair, eyes): Tyrosinase orchestrates the pigmentation process in humans, affecting skin, hair, and eye color. It is central to melanogenesis in melanocytes and is the primary molecular driver of both normal pigmentation and disorders of hyperpigmentation.
• Ocular system: OCA-associated TYR mutations cause poor visual acuity, nystagmus, iris transillumination, strabismus, photophobia, foveal hypoplasia, and misrouting of optic nerve fibers at the chiasm.
• Central nervous system: The dark pigment neuromelanin (NM) is abundant in cell bodies of dopamine neurons in the substantia nigra and norepinephrine neurons in the locus coeruleus in the human brain. During the progression of Parkinson's disease, together with the degeneration of the respective catecholamine neurons, the NM levels in the SN and LC markedly decrease.
• Oncology / immune system: In humans, tyrosinase is involved in the pigmentation in melanocytes, as a marker in melanoma patients, and as a target for the activation of prodrugs.
• Immune defense: In fungi, melanins are involved in defence mechanisms against stress factors such as UV or gamma radiation, free radicals, dehydration, and extreme temperatures.
• Gastrointestinal / nutritional context: Tyrosinase activity in foods determines postprandial exposure to phenolic oxidation products; from a dietary standpoint, consuming mushrooms and certain plant foods contributes enzymatic tyrosinase to the diet, though its systemic bioactivity following oral ingestion is not clinically established.

6. Inhibitors of Tyrosinase: Natural Sources and Mechanisms

Because tyrosinase is most frequently discussed in the context of inhibiting its activity, a comprehensive reference must address the major classes of natural and pharmaceutical tyrosinase inhibitors and their mechanisms.

6.1 Mechanisms of Inhibition

Melanogenesis inhibition can be obtained using three different methods: tyrosinase inhibition, copper chelation, and melanin-related protein downregulation. There are currently four different types of inhibitors characterized based on their enzyme inhibition mechanisms: competitive, uncompetitive, competitive/uncompetitive mixed-type, and noncompetitive inhibitors.

6.2 Kojic Acid

Kojic acid (KA), a fungal metabolite, is the most widely used skin-whitening agent, with possible side effects being dermatitis, sensitization, and erythema. Numerous contradicting mechanisms are described in the literature for KA as either a competitive or mixed inhibitor for mushroom tyrosinase, possibly by chelating copper in the active site.

6.3 Hydroquinone

Hydroquinone (HQ), another well-studied whitening agent, has been used clinically in leading cosmetic hyperpigmentation treatment; however, it was also found to cause serious problems by generating reactive oxygen species leading to oxidative damage of lipids and permanent loss of melanocytes. Hydroquinone received a controversial reputation for health and safety reasons since it is a metabolite of benzene, a known carcinogen. The long-term accumulation of hydroquinone is also associated with ochronosis, nephrotoxicity, and melanocyte toxicity.

6.4 Natural Botanical Inhibitors

The extracts and isolated compounds of numerous natural sources, in particular botanical sources, were well characterized with anti-tyrosinase activities and have been accepted as skin-lightening agents. The currently known skin-whitening and anti-melanin molecules include arbutin, deoxyarbutin, hydroquinone, deoxyarbutin derivatives, resorcinol, vanillin, niacinamide, kojic acid, arbutin-mimic isotachioside, hydroquinone derivatives (α- and β-arbutin), azelaic acid, L-ascorbic acid, ellagic acid, and tranexamic acid.

From Chinese herbal medicine, a natural product T1, bis(4-hydroxybenzyl)sulfide, isolated from the Chinese herbal plant Gastrodia elata, is a strong competitive inhibitor against mushroom tyrosinase (IC50 = 0.53 μM, Ki = 58 ± 6 nM), outperforming kojic acid. Cell viability and melanin quantification assay demonstrated that 50 μM of T1 apparently attenuates 20% melanin content of human normal melanocytes without significant cell toxicity. Moreover, the zebrafish in vivo assay reveals that T1 effectively reduces melanogenesis with no adverse side effects. These findings are, however, in vitro and zebrafish-based and have not yet been confirmed in human clinical trials.

7. Dosage Forms and Reported Dosages

Tyrosinase as an isolated enzyme preparation does not have established oral supplement dosages in clinical literature in the manner of, for example, a vitamin or mineral. Its primary application in human health is as a topical target (where inhibitors are applied to skin) and as a diagnostic/immunological biomarker. Reported dosages in the literature relate specifically to inhibitor compounds applied topically or tested in vitro:

• KT-939 lotion (clinical study): 0.2% KT-939 lotion was assessed in a 28-day, single-center clinical study in healthy women with sensitive skin.
• Thiamidol (clinical studies): Thiamidol formulations were applied for 3 months in both a vehicle-controlled, double-blinded, randomized clinical study and a clinical observational study for PIH. Exact percentage concentrations used in these formulations were not reported in publicly available abstracts reviewed.
• Deoxyarbutin (human trials): Deoxyarbutin showed significant improvements in solar lentigines and overall skin brightness in human clinical trials without cytotoxicity. Specific concentrations were not available in the accessed sources.
• Mushroom tyrosinase in food technology: Tyrosinase is a natural enzyme and is often purified to only a low degree, and it is involved in a variety of functions which mainly catalyze the o-hydroxylation of monophenols into their corresponding o-diphenols and the oxidation of o-diphenols to o-quinones using molecular oxygen, which then polymerizes to form brown or black pigments. It is employed in defined enzyme units in food bioprocessing applications rather than in human supplement dosing.
• T1 (bis(4-hydroxybenzyl)sulfide, in vitro and zebrafish): 50 μM of T1 apparently attenuates 20% melanin content of human normal melanocytes without significant cell toxicity, though this is a cellular concentration, not a human dosage.

No established oral human clinical dosages for tyrosinase as a dietary supplement have been identified in the peer-reviewed literature reviewed for this article.

8. Safety Considerations and Interactions

8.1 Safety of Tyrosinase Inhibitors Used in Clinical/Cosmetic Practice

Tyrosinase inhibitors are used for the prevention of severe skin diseases, in skin-whitening creams, and to avoid fruit browning; however, continued use of many such inhibitors is considered unsafe.

Kojic acid: Kojic acid is associated with erythema, stinging sensations, mild exfoliation, and contact eczema. Animal experiments suggested possible tumor promotion and weak carcinogenicity, and thus concentrations of 1% are recommended for safe human use. There are two major drawbacks of kojic acid: one is cytotoxicity, and the second is instability on storage.

Hydroquinone: HQ is a representative phenolic compound that is well known to cause toxicity against melanocytes. HQ is oxidized in melanocytes to produce highly toxic compounds such as quinone. These cytotoxic metabolites destroy melanocytes and cause skin bleaching. The theory of "bypass effect" or "melanocyte recovery" suggests that after sustained exposure to HQ, melanocytes become resistant and can no longer absorb HQ, thereby triggering melanin overproduction.

Arbutin and kojic acid (general): The most general tyrosinase inhibitors — arbutin and kojic acid — in cosmetics are also cytotoxic to normal cells and impenetrable into the dermal skin tissue. The usage of other oxidized leads of hydroperoxide and hydroquinone is prohibited due to their toxicity.

8.2 Autoimmune Risk from Anti-Tyrosinase Immunotherapy

Possible adverse effects of antityrosinase immunization, such as the destruction of normal melanocytes and its consequences, will have to be examined before clinical pilot studies can be undertaken. This is a specific concern in the context of cancer immunotherapy targeting tyrosinase as a melanoma-associated antigen, where on-target off-tumor effects (vitiligo-like depigmentation) are a recognized risk.

8.3 Neurological Safety Considerations

Dopamine in cytoplasm is highly reactive and is assumed to be oxidized spontaneously or by an unidentified tyrosinase to DAQ and then synthesized to NM. Intracellular NM accumulation above a specific threshold has been reported to be associated with dopamine neuron death and PD phenotypes. This relationship is relevant in the context of research into compounds that might alter brain tyrosinase activity — any such intervention would carry significant potential neurological risk and is not clinically established as a therapeutic approach.

8.4 Copper Chelation and Interactions

Because tyrosinase requires copper at its active site, melanogenesis inhibition can be obtained using copper chelation as one approach. This means that compounds capable of chelating copper — including many natural polyphenols — can inhibit tyrosinase by sequestering the metal cofactor. In high-dose supplementation contexts, the systemic copper-chelating effects of such compounds could theoretically impact copper homeostasis, though this has not been systematically studied in humans in the context of tyrosinase-targeted supplementation.

8.5 Regulatory Status

The clinical and commercial relevance of tyrosinase inhibitors has led to a surge in their integration into dermatological treatments and over-the-counter cosmeceuticals. These agents target a range of pigmentation disorders, and their success depends on both molecular efficacy and formulation sophistication. Many tyrosinase inhibitor compounds used in cosmetic and dermatological preparations are regulated as cosmetic ingredients or pharmaceutical active agents depending on jurisdiction, not as dietary supplements. The enzyme tyrosinase itself, as purified from mushroom sources, is used primarily as an industrial biocatalytic reagent rather than as an oral supplement with claimed health benefits.

9. Biotechnological and Industrial Applications

Tyrosinase is a natural enzyme involved in a variety of functions and mainly catalyzes the o-hydroxylation of monophenols into their corresponding o-diphenols and the oxidation of o-diphenols to o-quinones using molecular oxygen, which then polymerizes to form brown or black pigments. The synthesis of o-diphenols is a potentially valuable catalytic ability and thus tyrosinase has attracted a lot of attention with respect to industrial applications. These include synthesis of L-DOPA (the pharmaceutical precursor used in Parkinson's disease treatment), biosensor development, biodegradation of phenolic environmental contaminants, and food bioprocessing.

The role of human tyrosinase variants and their inhibitors is essential for developing therapeutic and cosmetic applications targeting hyperpigmentation disorders. Structural characterizations of tyrosinase-inhibitor complexes provide a foundation for designing effective inhibitors, with compounds like kojic acid, L-mimosine, and (S)-3-amino-tyrosine demonstrating significant inhibitory potential.

10. Limitations and Gaps in Current Evidence

Several critical limitations must be acknowledged in assessing the scientific evidence base for tyrosinase:

• The vast majority of in vitro tyrosinase inhibition studies use mushroom (Agaricus bisporus) tyrosinase as the experimental target, which shares homology with but differs significantly from human tyrosinase. Most identified inhibitors lack clinical efficacy because they were identified using mushroom tyrosinase as the target.
• Cellular melanin assays using murine melanoma cell lines (e.g., B16-F10) may also fail to predict human clinical efficacy.
• Human clinical trials for topical tyrosinase-inhibiting preparations are heterogeneous in design, often small, single-center, and of short duration.
• Tyrosinase as an oral dietary supplement lacks any peer-reviewed human clinical trial evidence for systemic health claims as of the literature reviewed here.
• The role of tyrosinase in Parkinson's disease is mechanistically intriguing but remains investigational; no clinical intervention has been established.
• Dysregulation of the melanogenesis pathway underlies hyperpigmentation disorders, including melasma, post-inflammatory hyperpigmentation, and solar lentigines, while its broader roles in neurodegenerative oxidative stress and in enzymatic browning of foods establish it as a multidisciplinary therapeutic and industrial target, but translating this mechanistic understanding into human therapies remains an active area of ongoing research.

References

• Di Costanzo LF. Structural characterization of tyrosinases and an update on human enzymes. Enzymes. 2024;56:55-83. PubMed.
• Olivares C, Solano F. New insights into the active site structure and catalytic mechanism of tyrosinase and its related proteins. Pigment Cell Melanoma Res. 2009. PubMed.
• Solano F. Tyrosinase enzyme: 1. An overview on a pharmacological target. Mini Rev Med Chem. 2014. PubMed.
• Seo SY, Sharma VK, Sharma N. Purification and characterization of melanogenic enzyme tyrosinase from button mushroom. J Food Sci. 2003. PMC.
• Rangarajan S et al. Tyrosinase inhibitors from natural and synthetic sources: structure, inhibition mechanism and perspective for the future. PMC. 2024.
• Zaidi KU et al. Microbial Tyrosinases: Promising Enzymes for Pharmaceutical, Food Bioprocessing, and Environmental Industry. Biochem Res Int. 2014. PMC.
• Goulgouti N et al. Anti-Melanogenic Properties of Greek Plants. A Novel Depigmenting Agent from Morus alba Wood. Molecules. 2018. PMC.
• Park J et al. Naturally-Occurring Tyrosinase Inhibitors Classified by Enzyme Kinetics and Copper Chelation. Cosmetics. 2023. PMC.
• Lai X et al. The unravelling of the complex pattern of tyrosinase inhibition. Sci Rep. 2016. PMC.
• Carballo-Carbajal I et al. Brain tyrosinase overexpression implicates age-dependent neuromelanin production in Parkinson's disease pathogenesis. Nat Commun. 2019;10:973. PMC.
• Nagatsu T, Nakashima A, Ichinose H, Kobayashi K. Neuromelanin in Parkinson's Disease: Tyrosine Hydroxylase and Tyrosinase. Front Neurol. 2022. PMC.
• Nagatsu T et al. The role of tyrosine hydroxylase as a key player in neuromelanin synthesis and the association of neuromelanin with Parkinson's disease. J Neural Transm. 2023. PMC.
• van der Bruggen P et al. The tyrosinase gene codes for an antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas. J Exp Med. 1994. PMC.
• Hamid O et al. Immunotherapy for Melanoma: Current Status and Perspectives. J Investig Dermatol Symp Proc. 2012. PMC.
• Fetsch PA et al. Immunophenotyping of melanomas for tyrosinase: implications for vaccine development. Proc Natl Acad Sci USA. 1997. PMC.
• Lin S et al. Evidence that the Ser192Tyr/Arg402Gln in cis Tyrosinase gene haplotype is a disease-causing allele in oculocutaneous albinism type 1B (OCA1B). NPJ Genomic Med. 2022. PMC.
• Hosseini R et al. Two Novel Tyrosinase (TYR) Gene Mutations with Pathogenic Impact on Oculocutaneous Albinism Type 1 (OCA1). PLoS One. 2014. PMC.
• Parvez S et al. An Updated Review of Tyrosinase Inhibitors. Phytother Res. 2007. PMC.
• Bae WY et al. Increased therapeutic efficacy of a newly synthesized tyrosinase inhibitor by solid lipid nanoparticles in the topical treatment of hyperpigmentation. Int J Nanomedicine. 2016. PMC.
• Mann T et al. Effective reduction of post-inflammatory hyperpigmentation with the tyrosinase inhibitor isobutylamido-thiazolyl-resorcinol (Thiamidol). J Eur Acad Dermatol Venereol. 2021. PMC.
• KT-939: A Next-Generation Human Tyrosinase Inhibitor With Superior Efficacy for the Safe Management of Hyperpigmentation. J Cosmet Dermatol. 2025. PMC.
• Chen R et al. Prevention of Enzymatic Browning by Natural Extracts and Genome-Editing: A Review on Recent Progress. Foods. 2022. PMC.
• Gonçalves R et al. Recent Trends in Controlling the Enzymatic Browning of Fruit and Vegetable Products. Processes. 2020. PMC.
• Lim JY et al. Multifunctional Tyrosinase Inhibitor Peptides with Copper Chelating, UV-Absorption and Antioxidant Activities: Kinetic and Docking Studies. Mar Drugs. 2021. PMC.
• Kim YJ, Uyama H. Melanocytotoxic chemicals and their toxic mechanisms. Toxicol Res. 2022. PMC.
• Ito S et al. Tyrosinase-Expressing Neuronal Cell Line as in Vitro Model of Parkinson's Disease. PLoS One. 2010. PMC.
• Zhu Y et al. Discovery of Highly Potent Tyrosinase Inhibitor, T1, with Significant Anti-Melanogenesis Ability by zebrafish in vivo Assay and Computational Molecular Modeling. Sci Rep. 2015.
• Chen J et al. Tyrosinase inhibitors: Molecular mechanisms, therapeutic potentials, and translational applications in dermatology and beyond. ScienceDirect. 2026.
• RCSB PDB – 2Y9X: Crystal structure of PPO3, a tyrosinase from Agaricus bisporus. Biochemistry 2011;50:5477.
• Kumar P et al. Kojic Acid Peptide: A New Compound with Anti-Tyrosinase Potential. PMC. 2016.